Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Fundamental Analysis

NYSEARCA:XTNT - NYSE Arca - US98420P3082 - Common Stock - Currency: USD

0.7073  +0.03 (+3.71%)

Fundamental Rating

2

XTNT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of XTNT have multiple concerns. While showing a medium growth rate, XTNT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XTNT has reported negative net income.
XTNT had a negative operating cash flow in the past year.
In the past 5 years XTNT reported 4 times negative net income.
XTNT had negative operating cash flow in 4 of the past 5 years.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -12.51%, XTNT perfoms like the industry average, outperforming 58.51% of the companies in the same industry.
XTNT's Return On Equity of -27.33% is in line compared to the rest of the industry. XTNT outperforms 57.45% of its industry peers.
Industry RankSector Rank
ROA -12.51%
ROE -27.33%
ROIC N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

XTNT has a Gross Margin of 58.18%. This is comparable to the rest of the industry: XTNT outperforms 54.79% of its industry peers.
In the last couple of years the Gross Margin of XTNT has declined.
The Profit Margin and Operating Margin are not available for XTNT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

XTNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
XTNT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XTNT has been increased compared to 5 years ago.
The debt/assets ratio for XTNT is higher compared to a year ago.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -1.18, we must say that XTNT is in the distress zone and has some risk of bankruptcy.
XTNT's Altman-Z score of -1.18 is on the low side compared to the rest of the industry. XTNT is outperformed by 62.23% of its industry peers.
XTNT has a Debt/Equity ratio of 0.51. This is a neutral value indicating XTNT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.51, XTNT is in line with its industry, outperforming 41.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z -1.18
ROIC/WACCN/A
WACC9.28%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.34 indicates that XTNT has no problem at all paying its short term obligations.
XTNT's Current ratio of 2.34 is in line compared to the rest of the industry. XTNT outperforms 43.09% of its industry peers.
XTNT has a Quick Ratio of 1.03. This is a normal value and indicates that XTNT is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.03, XTNT is not doing good in the industry: 75.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.03
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for XTNT have decreased strongly by -800.00% in the last year.
Looking at the last year, XTNT shows a very strong growth in Revenue. The Revenue has grown by 20.81%.
XTNT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.64% yearly.
EPS 1Y (TTM)-800%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)20.81%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.05%

3.2 Future

The Earnings Per Share is expected to grow by 36.84% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.41% on average over the next years. This is quite good.
EPS Next Y70.25%
EPS Next 2Y36.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.24%
Revenue Next 2Y8.41%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2023 2024 2025 2026 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XTNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XTNT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as XTNT's earnings are expected to grow with 36.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XTNT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (6/5/2025, 8:18:37 PM)

0.7073

+0.03 (+3.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners16.96%
Inst Owner Change-0.37%
Ins Owners7.73%
Ins Owner Change-0.05%
Market Cap98.54M
Analysts85
Price Target1.79 (153.08%)
Short Float %0.04%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.64%
Min EPS beat(2)-30.72%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-8.66%
Min EPS beat(4)-56.86%
Max EPS beat(4)100%
EPS beat(8)3
Avg EPS beat(8)37.09%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.27%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)3.39%
Revenue beat(4)2
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)3.39%
Revenue beat(8)6
Avg Revenue beat(8)4.72%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-2.79%
Revenue NQ rev (3m)-8.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 2.25
P/tB 3.44
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.88
BVpS0.31
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.51%
ROE -27.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.18%
FCFM N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score2
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 105.54%
Cap/Sales 3.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 1.03
Altman-Z -1.18
F-Score2
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-800%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y70.25%
EPS Next 2Y36.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)20.81%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.05%
Revenue Next Year9.24%
Revenue Next 2Y8.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year167.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.12%
OCF growth 3YN/A
OCF growth 5YN/A